Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
pSivida Corp Company Overview 5
pSivida Corp Company Snapshot 5
pSivida Corp Pipeline Products and Ongoing Clinical Trials Overview 5
pSivida Corp – Pipeline Analysis Overview 8
pSivida Corp – Key Facts 8
pSivida Corp – Major Products and Services 9
pSivida Corp Pipeline Products by Development Stage 10
pSivida Corp Ongoing Clinical Trials by Trial Status 12
pSivida Corp Pipeline Products Overview 14
Durasert – Back Of Eye Disease 14
Durasert – Back Of Eye Disease Product Overview 14
Durasert – Front Of Eye Disease 15
Durasert – Front Of Eye Disease Product Overview 15
Durasert – Knee Osteoarthritis 16
Durasert – Knee Osteoarthritis Product Overview 16
Durasert – Knee Osteoarthritis Clinical Trial 17
Durasert – Posterior Segment Uveitis 18
Durasert – Posterior Segment Uveitis Product Overview 18
Durasert – Posterior Segment Uveitis Clinical Trial 19
Durasert Latanoprost Implant 20
Durasert Latanoprost Implant Product Overview 20
DURASERT With TKI – Wet AMD 21
DURASERT With TKI – Wet AMD Product Overview 21
Next Gen Duraset – Posterior Segment Uveitis 22
Next Gen Duraset – Posterior Segment Uveitis Product Overview 22
Tethadur System 23
Tethadur System Product Overview 23
pSivida Corp – Key Competitors 24
pSivida Corp – Key Employees 25
pSivida Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
pSivida Corp, Recent Developments 27
Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 27
Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 27
Jul 18, 2017: Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences 28
Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 29
Jun 22, 2017: pSivida Submits Marketing Authorization Application for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union 29
Jun 13, 2017: pSivida’s Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study 30
May 08, 2017: Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months 31
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 31
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 32
May 04, 2017: pSivida Provides Update On Durasert 33
Appendix 34
Methodology 34
About GlobalData 36
Contact Us 36
Disclaimer 37
pSivida Corp Pipeline Products and Ongoing Clinical Trials Overview 5
pSivida Corp Pipeline Products by Equipment Type 6
pSivida Corp Pipeline Products by Indication 7
pSivida Corp Ongoing Clinical Trials by Trial Status 7
pSivida Corp, Key Facts 8
pSivida Corp, Major Products and Services 9
pSivida Corp Number of Pipeline Products by Development Stage 10
pSivida Corp Pipeline Products Summary by Development Stage 11
pSivida Corp Ongoing Clinical Trials by Trial Status 12
pSivida Corp Ongoing Clinical Trials Summary 13
Durasert - Back Of Eye Disease - Product Status 14
Durasert - Back Of Eye Disease - Product Description 14
Durasert - Front Of Eye Disease - Product Status 15
Durasert - Front Of Eye Disease - Product Description 15
Durasert - Knee Osteoarthritis - Product Status 16
Durasert - Knee Osteoarthritis - Product Description 16
Durasert - Knee Osteoarthritis - A Pilot Study of a Dexamethasone Implant System in Humans 17
Durasert - Posterior Segment Uveitis - Product Status 18
Durasert - Posterior Segment Uveitis - Product Description 18
Durasert - Posterior Segment Uveitis - A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye 19
Durasert - Posterior Segment Uveitis - A Phase III, Multi-national, Multi-center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye 19
Durasert Latanoprost Implant - Product Status 20
Durasert Latanoprost Implant - Product Description 20
DURASERT With TKI - Wet AMD - Product Status 21
DURASERT With TKI - Wet AMD - Product Description 21
Next Gen Duraset - Posterior Segment Uveitis - Product Status 22
Next Gen Duraset - Posterior Segment Uveitis - Product Description 22
Tethadur System - Product Status 23
Tethadur System - Product Description 23
pSivida Corp, Key Employees 25
pSivida Corp, Subsidiaries 26
Glossary 35